![]() ![]() Schwarz Pharma had acquired these rights from Genentech in 1999, submitted European registration documents and received NutropinAq marketing approval. ¿ Schwarz Pharma AG, of Monheim, Germany, and Genentech Inc., of South Francisco, signed an agreement under which Genentech reacquired the exclusive development and marketing rights to NutropinAq and NutropinDepot recombinant human growth hormone products in Europe and certain other countries outside the United States, Canada, China and Japan. November will get DM1.1 million of the grant. The German Ministry of research and Education is fueling the project with a DM10 million (US$4.3 million) grant. November plans to contribute its DNA electrohybridization technique. The companies want to design them to be cheaper than conventional biochips. The chips for use in hospital labs and medical service labs are expected to work on electrical detection without further optical labeling. ¿ November AG, of Erlangen, Germany, along with the medical technology branch of the electric corporation Siemens AG, of Munich, chip foundry Infineon AG, of Munich, laboratory device vendor Eppendorf Instrumente GmbH, of Hamburg, and the Fraunhofer Institute for Silicon Technology, of Itzehoe, Germany, plan to develop in a joint project silicon DNA chips for molecular diagnosis. NS2330 also is the subject of a Phase II clinical study in Parkinson¿s patients with dyskinesia. Sheldon Preskorn, of the Psychiatric Research Institute in Wichita, Kan., and Cognitive Drug Research Ltd., of Reading, UK, performed the study. The two highest doses, according to NeuroSearch, ¿produced significant improvement of major components of cognitive function,¿ while all four doses were well tolerated. Four separate dosage groups, each containing eight patients with mild Alzheimer¿s, were assessed at baseline and at 28 and 42 days. ¿ NeuroSearch A/S, of Ballerup, Denmark, said it obtained promising results in a double-blind, placebo-controlled Phase II clinical study of its Alzheimer¿s candidate, NS2330. The libraries containing highly diverse compounds will be quality controlled regarding purity and identity of the compounds, Evotec spokeswoman Anne Hennecke said. Hoffmann-La Roche Ltd., of Basel, Switzerland, to be used in Roche¿s drug discovery screening programs. ¿ Evotec OAI, of Hamburg, Germany, signed a one-year contract to supply chemical compound libraries to F. Diatos¿ researchers will be working in close cooperation with the university¿s cell biology laboratory, headed by Andri Trouet. They will have joint ownership of joint discoveries, and the university will grant Diatos an exclusive worldwide license for the application of this technology in the field of oncology. The partners will pool their respective proprietary technologies to accelerate the development of both tumor-activated drugs ¿ cytoxic drugs liberated by peptides directly into the tissue where the tumor is ¿ and drug delivery systems. ¿ Diatos SA, of Paris, entered into a three-year research and development collaboration with the Catholic University of Louvain. ![]() The initial research agreement involves Xerion paying a license fee to CAT. CAT CEO David Chiswell said the combination of CAT¿s antibody library and Xerion¿s skills in determining protein function should build significant future value. Xerion has a functional proteomics platform that it is applying to novel target discovery. ¿ Cambridge Antibody Technology Group plc, of Melbourn, UK, agreed to a licensing deal with Xerion Pharmaceuticals GmbH, of Martinsried, Germany, giving Xerion access to CAT¿s human phage antibody library for target discovery and validation. Bionomics owns the rights to the genes and Ozgene will contribute genetic tools and models to help with the development work, in return for a share of the royalties on any resulting products. and Ozgene Pty Ltd., both of Adelaide, Australia, formed a strategic alliance to develop treatments involving three genes believed to be involved in breast cancer. This is the second of four payments, with the next installment of #7 million due in June 2002, and the fourth of #7 million due in June 2003. Baxter now owns 11.7 million shares, or 12.8 percent of Acambis. ¿ Acambis plc, of Cambridge, UK, said it received the second tranche of #3.5 million (US$4.8 million) of equity investment from Baxter International Inc., as agreed when the two set up a vaccines collaboration in September 2000. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |